Sector Gamma As is an investment fund managing more than $268 billion ran by Janicke Forde. There are currently 28 companies in Forde’s portfolio. The largest investments include Gilead Sciences and Pfizer, together worth $53.9 billion.
As of 2nd August 2024, Sector Gamma As’s top holding is 420,163 shares of Gilead Sciences currently worth over $28.8 billion and making up 10.8% of the portfolio value.
Relative to the number of outstanding shares of Gilead Sciences, Sector Gamma As owns more than approximately 0.1% of the company.
In addition, the fund holds 895,000 shares of Pfizer worth $25 billion, whose value grew 4.4% in the past six months.
The third-largest holding is Bristol-Myers Squibb Co worth $22.2 billion and the next is Medtronic Plc worth $20.8 billion, with 264,890 shares owned.
Currently, Sector Gamma As's portfolio is worth at least $268 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Sector Gamma As office and employees reside in Oslo, Norway. According to the last 13-F report filed with the SEC, Janicke Forde serves as the Head of fund operations at Sector Gamma As.
In the most recent 13F filing, Sector Gamma As revealed that it had opened a new position in
AMGEN and bought 30,000 shares worth $9.37 billion.
This means they effectively own approximately 0.1% of the company.
AMGEN makes up
4.1%
of the fund's Health Care sector allocation and has grown its share price by 25.2% in the past year.
The investment fund also strengthened its position in Gilead Sciences by buying
154,544 additional shares.
This makes their stake in Gilead Sciences total 420,163 shares worth $28.8 billion.
Gilead Sciences dropped 5.7% in the past year.
On the other hand, there are companies that Sector Gamma As is getting rid of from its portfolio.
Sector Gamma As closed its position in Globus Med Inc on 9th August 2024.
It sold the previously owned 105,381 shares for $5.65 billion.
Janicke Forde also disclosed a decreased stake in Pfizer by 0.3%.
This leaves the value of the investment at $25 billion and 895,000 shares.
The two most similar investment funds to Sector Gamma As are Clean Yield and Empower Annuity Insurance Co. They manage $268 billion and $268 billion respectively.
Sector Gamma As’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 85.2% of
the total portfolio value.
The fund focuses on investments in the United States as
71.4% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
61% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $56.1 billion.
These positions were updated on August 9th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Gilead Sciences, Inc. |
58.18%
420,163
|
$28,827,383,000 | 10.77% |
| Pfizer Inc. |
27.77%
895,000
|
$25,042,100,000 | 9.36% |
| Bristol-Myers Squibb Co. |
7.31%
535,000
|
$22,218,550,000 | 8.30% |
| Medtronic Plc |
35.69%
264,890
|
$20,849,492,000 | 7.79% |
| Elevance Health Inc |
29.21%
24,279
|
$13,155,819,000 | 4.91% |
| CVS Health Corp |
28.57%
220,000
|
$12,993,200,000 | 4.85% |
| Incyte Corp. |
23.22%
203,376
|
$12,328,653,000 | 4.61% |
| Cardinal Health, Inc. |
41.34%
107,098
|
$10,529,875,000 | 3.93% |
| Biogen Inc |
26.32%
43,985
|
$10,196,603,000 | 3.81% |
| AMGEN Inc. |
Opened
30,000
|
$9,373,500,000 | 3.50% |
| Zimmer Biomet Holdings Inc |
29.77%
85,000
|
$9,225,050,000 | 3.45% |
| Baxter International Inc. |
19.53%
260,000
|
$8,697,000,000 | 3.25% |
| Ge Healthcare Technologies I |
15.54%
104,000
|
$8,103,680,000 | 3.03% |
| Ionis Pharmaceuticals Inc |
3.14%
170,000
|
$8,102,200,000 | 3.03% |
| Bruker Corp |
2.39%
115,472
|
$7,368,268,000 | 2.75% |
| Abbott Labs |
Opened
70,000
|
$7,273,700,000 | 2.72% |
| Tenet Healthcare Corp. |
31.82%
52,861
|
$7,032,099,000 | 2.63% |
| Universal Hlth Svcs Inc |
49.91%
35,000
|
$6,472,550,000 | 2.42% |
| Edwards Lifesciences Corp |
35.29%
69,153
|
$6,387,663,000 | 2.39% |
| Globus Med Inc |
Closed
105,381
|
$5,652,637,000 | |
| Agios Pharmaceuticals Inc |
25.88%
121,844
|
$5,253,913,000 | 1.96% |
| Biomarin Pharmaceutical Inc. |
22.19%
63,348
|
$5,215,441,000 | 1.95% |
| Alkermes plc |
23.11%
194,000
|
$4,675,400,000 | 1.75% |
| Bio Rad Labs Inc |
50.01%
16,829
|
$4,596,168,000 | 1.72% |
| Alnylam Pharmaceuticals Inc |
44.75%
15,240
|
$3,703,320,000 | 1.38% |
| Qiagen NV |
19.24%
83,484
|
$3,430,358,000 | 1.28% |
| Centene Corp. |
102.56%
45,000
|
$2,983,500,000 | 1.11% |
| Lantheus Holdings Inc |
40.23%
31,712
|
$2,546,156,000 | 0.95% |
| Illumina Inc |
Closed
17,000
|
$2,334,440,000 | |
| Viatris Inc. |
75.31%
103,106
|
$1,096,017,000 | 0.41% |
| No transactions found | |||
| Showing first 500 out of 30 holdings | |||